10x Genomics Q1 2024 Earnings Report

10x Genomics EPS Results

• Actual EPS: -$0.50
• Consensus EPS: -$0.50
• Beat/Miss: Met Expectations
• One Year Ago EPS: -$0.44

10x Genomics Revenue Results

• Actual Revenue: $141.01 million
• Expected Revenue: $142.24 million
• Beat/Miss: Missed by -$1.23 million
• YoY Revenue Growth: +5.00%

10x Genomics Announcement Details

• Quarter: Q1 2024
• Date: 4/30/2024
• Time: After Market Closes

10x Genomics (NASDAQ:TXG), a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.